Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report

Studies have been actively conducted to identify actionable mutations and incorporate them into clinical practice in pancreatic ductal adenocarcinoma (PDAC), which is known to have a poor prognosis with traditional cytotoxic chemotherapy. A BRAF point mutation in V600E is commonly reported in KRAS w...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Ji Eun, An, Ho Jung, Park, Hyung Soon, Kim, Hyunho, Shim, Byoung Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731151/
https://www.ncbi.nlm.nih.gov/pubmed/36505826
http://dx.doi.org/10.3389/fonc.2022.976450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731151/
https://www.ncbi.nlm.nih.gov/pubmed/36505826
http://dx.doi.org/10.3389/fonc.2022.976450

Ejemplares similares